Tonix Pharmaceuticals Announces Research Collaboration With Columbia University To Study Recombinant Trefoil Factor 2 Based Therapy For Gastric And Colorectal Cancers

TNX-1700 is Under Development as Monotherapy and in Combination with Anti-PD1 Checkpoint Inhibitor Therapy in Animal Models of Two Challenging Cancers
 

In Mouse Models, rTFF2 Detoxifies the Tumor Microenvironment,

TNX-1700 is Under Development as Monotherapy and in Combination with Anti-PD1 Checkpoint Inhibitor Therapy in Animal Models of Two Challenging Cancers
 

In Mouse Models, rTFF2 Detoxifies the Tumor Microenvironment, Allows Activation of Cancer-Killing CD8+T Cells and Limits Immune Evasion by Cancer Cells

Study to be Led by Noted Cancer Researcher and Columbia Professor Timothy C. Wang, M.D.